Christina Sorbe

Christina Sorbe

Auto-generated profile, based on publicly available information

Christina Sorbe

Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Life
Verified
Journal Article
Open access
PDF file
NKNatalia Kirsten
Natalia Kirsten
SRStephan Rustenbach
Stephan Rustenbach
RKRalph M. von Kiedrowski
Ralph M. von Kiedrowski
CSChristina Sorbe
Christina Sorbe
KRKristian Reich
Kristian Reich
MAMatthias Augustin
Matthias Augustin
In psoriasis treatment, there is a high need to define meaningful endpoints and differences from the patient perspective to analyze patient-relevant differences of frequently used outcome methods for psoriasis under real-world conditions. A sample of 3116 patients from the German Psoriasis-Registry PsoBest was analyzed for clinical as well as patient-reported outcomes (PRO) after 3- and 6-month treatment. The parameters PASI, DLQI, and PBI were intercorrelated and related to two anchoring variables: (1) patient satisfaction with treatment and (2) perceived complete clearance. Baseline data were as follows: PASI 10.5 ± 9.1, DLQI 12.4 ± 3.4, and PBI 2.7 ± 0.3. There was an almost linear relationship between “complete patient satisfaction” and the relative differences in PASI in the range from PASI 25 to PASI 90. However, there was no additional benefit between PASI 90 and PASI 100. The same finding resulted from the anchoring variable “perception of complete healing”. When related to DLQI outcomes, relative PASI changes as well as absolute changes and PASI at 3 and 6 months showed relevant differences between the PASI classes 25 to 90 but not between PASI 90 and PASI 100. Under real-world conditions, changes in PASI and DLQI reflect patient-relevant benefits.

12 December 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
FVFabio Verardi
Fabio Verardi
LMLara Valeska Maul
Lara Valeska Maul
KBKim Borsky
Kim Borsky
SSSimona Steinmann
Simona Steinmann
NRNina Rosset
Nina Rosset
JMJulia-Tatjana Maul
Julia-Tatjana Maul

1 January 2026 in Psoriasis: Targets and Therapy
Verified
Journal Article
Open access
PDF file
TJToni Maria Janke
Toni Maria Janke
CSChristina Sorbe
Christina Sorbe
RSRachel Sommer
Rachel Sommer
TBThomas Bickert
Thomas Bickert
UMUlrich Mrowietz
Ulrich Mrowietz
MAMatthias Augustin
Matthias Augustin
Purpose: Psoriatic disease (PsO) involving the genital region (GenPsO) or areas of sexual interest (ASI; anal region, gluteal area, groin, lower back, and chest/breast) is associated with impaired quality of life (QoL), sexual burden, and avoidance of sexual life. This nested cohort study investigated the prevalence and effect of GenPsO and PsO at any ASI in routine German care. Methods: Adult patients enrolled in the PsoBest registry were surveyed by mail. Main endpoints were prevalences of GenPsO and PsO at any ASI in the past 12 and 24 months. The reasons for sexual impairment (RSI) questionnaire, the Genital Psoriasis Symptoms Scale (GPSS), the Genital Psoriasis Sexual Impact Scale, demographics, and disease characteristics were assessed. Results: Questionnaires were returned by 811/2010 (40.3%) patients; 795 (39.6%) complete sets were analyzed. Mean (SD) age at onset was 35.0 (14.0) years for GenPsO, and 34.1 (14.9) years for PsO at any ASI. Period prevalence was 21.6% (n=172) for GenPsO and 49.2% (n=391), for PsO at any ASI in the last 24 months, and 10.8% (n=86) and 26.7% (n=212), respectively, at day of survey. Systemic therapy was used by 84.9% (n=73) of patients with GenPsO and 83.0% (n=176) with PsO at any ASI. Mean (SD) GPSS sum score was 27.6 (18.6). In the past 30 days, 60.5% (n=52) of patients with GenPsO and 35.4% (n=75) with PsO at any ASI experienced sexual impairment. Among patients with GenPsO, 40.7% (n=35) reported always avoiding sexual activities during the past week. RSI included stress, lack of self-confidence, and PsO-related pain/movement restrictions. Conclusion: Given the high prevalence of GenPsO and its extensive effect on patient QoL and sexual well-being, it is essential that genital and ASI regions are examined at each routine clinical appointment and that appropriate treatment is offered to minimize negative consequences and cumulative life course impairment.

1 October 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
CBChristine Blome
Christine Blome
CSCatharina C. von Stülpnagel
Catharina C. von Stülpnagel
MAMatthias Augustin
Matthias Augustin
UMUlrich Mrowietz
Ulrich Mrowietz
KRKristian Reich
Kristian Reich
TKToni M. Klein
Toni M. Klein

Verified
Journal Article
Open access
PDF file
BSBrigitte Stephan
Brigitte Stephan
SRStephan Jeff Rustenbach
Stephan Jeff Rustenbach
NBNesrine Ben-Anaya
Nesrine Ben-Anaya
MAMatthias Augustin
Matthias Augustin
WBWolf-Henning Boehncke
Wolf-Henning Boehncke
CSChristina Sorbe
Christina Sorbe
Background: Patients with psoriasis under systemic treatments are in focus regarding their susceptibility to respiratory infections. To analyse real-world data for respiratory infections in patients with psoriasis under systemic treatments. Methods: We analysed data of the prospective, non-interventional German Psoriasis Registry PsoBest and compared rates for respiratory infections of 13,823 patients on systemic treatments for psoriasis and/or psoriatic arthritis in different therapy cohorts before the COVID-19 pandemic. Results: In total, 1415 respiratory infections were observed in 970 patients. Significant differences were observed between biologics and non-biologics, but not within these groups. The highest event rates (events/100 patient years) were identified for TNF-α inhibitors, 8.1, (CI 7.4–8.9), followed by 7.0 for IL-17 inhibitors (6.2–7.9), 5.7 for IL-12/23 and IL-23 inhibitors (5.1–6.5), 4.8 for methotrexate (4.3–5.4), 3.7 for small molecules (3.3–4.2), and 2.7 for retinoids (1.2–5.1). Conclusions: Overall, the susceptibility for respiratory infections in patients under systemic therapy for psoriasis is low compared to published study data and is sufficient as comparative data for COVID-19 studies.

27 November 2025 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
NBNesrine Ben-Anaya
Nesrine Ben-Anaya
TYTony Yip
Tony Yip
CSChristina Sorbe
Christina Sorbe
TBThomas Bickert
Thomas Bickert
JHJohannes Hockmann
Johannes Hockmann
RKRalph M. von Kiedrowski
Ralph M. von Kiedrowski
Psoriasis involving the genital region (GenPsO) is associated with impaired quality of life (QoL), including sexual burden and avoidance of sexual intercourse. There is limited data on the effectiveness of risankizumab in GenPsO on patients' QoL and sexual impairment. GPS-Best, a nested cohort non-interventional study within the German Psoriasis registry PsoBest, aims to evaluate the effectiveness of risankizumab in GenPsO and its impact on QoL and sexual impairment. This interim analysis involves 52 patients who completed week 16 of the 52-week GPS-Best study. Patient questionnaires, including the Genital Psoriasis Symptoms Scale (GPSS) and Genital Psoriasis Sexual Impact Scale (GPSIS), were evaluated in patients with plaque psoriasis and a static physician's global assessment of genitalia ≥ 3 at baseline. The results demonstrated a significant reduction in the GPSS total score from a median [IQR] of 42.0 [36.0-57.0] at baseline to 3.0 [0-9.0] at week 16 (p < 0.001). In the GPSIS avoidance and impact subscale, more patients reported 'never' avoiding sexual activity at week 16 compared to baseline (46.8% vs. 10.5%) and 78.9% reported 'no or very low' impact compared to 18.5% at baseline, respectively. These findings indicate risankizumab significantly reduces patient-reported GenPsO symptoms over a 16-week period and increases sexual QoL.